Table 5.
Quality of life and symptoms of patients and lung cancer module QLQ‐LC13 analysis
| Symptoms scale† | Dyspnea | Total scale‡ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | Interval Change (95% CI) | P‐value | Mean | Interval change (95% CI) | P‐value | Mean | Interval change (95% CI) | P‐value | |
| Baseline | 27.09 | ‐ | ‐ | 36.11 | ‐ | ‐ | 19.16 | ‐ | ‐ |
| D1 | 23.96 | −3.13 (−9.47, +3.22) |
0.215 | 25.99 | −11.11 (−36.11, +13.89) |
0.252 | 17.08 | −2.08 (−6.31, +2.15) |
0.215 |
| D7 | 20.83 | −6.25 (−28.24, +15.74) |
0.432 | 22.22 | −13.89 (−44.08, +16.30) |
0.239 | 14.99 | −4.17 (−21.30, +12.97) |
0.496 |
| D21 | 10.42 | −16.67 (−36.19, +2.85) |
0.073 | 5.56 | −30.55 (−52.80, −8.31) |
0.022 | 6.95 | −12.21 (−25.07, +0.65) |
0.057 |
†
Cough, hemoptysis, dyspnea, and site‐specific pain.
‡
Lung cancer‐associated symptoms (cough, hemoptysis, dyspnea, and site‐specific pain) and treatment‐related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia).